2023-10-24T11:16:09-05:00 2022-12-31 411431613 BERGANKDV LTD 2451 OAKDALE BLVD - STE 204 CORALVILLE IA 52241 990 2022-01-01 205239366 JOHN PAUL II MEDICAL RESEARCH INSTITUTE JOHN 3196887367 2500 CROSSPARK RD E108 CORALVILLE IA 52241 JAY KAMATH PRESIDENT 3196887367 2023-10-23 1 JAY KAMATH 999009999 0 BRIAN ARONSON CPA P01425251 3193543000 2023-10-23 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z X JAY KAMATH 2500 CROSSPARK RD E108 CORALVILLE IA 52241 469748 0 X WWW.JP2MRI.ORG X 2006 IA ADVOCATES FOR MEDICAL RESEARCH THAT RECOGNIZES THE DIGNITIY OF HUMAN LIFE FROM THE MOMENT OF CONCEPTION TO NATURAL DEATH AND ADDRESS UNMET MEDICAL NEEDS. 6 4 7 6 0 0 775994 464437 0 4953 196 358 0 0 776190 469748 0 0 0 0 136418 222166 142 0 5260 228512 297594 365072 519760 411118 -50012 513407 509156 123199 168960 390208 340196 X THE JOHN PAUL II MEDICAL RESEARCH INSTITUTE (JP2MRI) SEEKS TO FIND CURES AND THERAPIES EXCLUSIVELY USING A VARIETY OF ADULT STEM CELLS AND INDUCED PLURIPOTENT STEM CELLS. THE INSTITUTE DOES NOT ENGAGE IN EMBRYONIC STEM CELL RESEARCH OF ANY KIND. JP2MRI DEVELOPS PRECLINICAL RESEARCH TECHNOLOGIES THAT WILL BROADLY ADVANCE DRUG DISCOVERY AND REGENERATIVE MEDICINE FOR MANY DISEASES. IN ADDITION, THE INSTITUTE WILL ENGAGE IN EDUCATIONAL OUTREACH TO INCREASE THE NUMBER OF SCIENTISTS AND FUTURE MEDICAL PRACTITIONERS WHO WILL WORK WITH ADULT STEM CELLS, ALWAYS WITH AN EMPHASIS ON MEDICAL BIOETHICS THAT IS CONSISTENT WITH THE DIGNITY OF HUMAN LIFE. 0 0 267357 TO DEVELOP A COLLABORATIVE BASIC AND CLINICAL RESEARCH PROGRAM IN OUR FOUR CORE RESEARCH AREAS: CANCER, NEURODEGENERATIVE DISEASES, RARE DISEASES, AND ADULT STEM CELL THERAPIES. IN 2022, JP2MRI CONTINUED OUR RESEARCH EFFORTS INTO DEVELOPING A SAFER AND MORE ROBUST CORONAVIRUS VACCINE UTILIZING A TRADITIONAL NON-MRNA BASED APPROACH THAT WAS FREE OF ABORTED FETAL TISSUE IN DEVELOPMENT AND TESTING. POTENTIAL VACCINE CANDIDATES THE INSTITUTE DEVELOPED WERE SENT TO THE UNIVERSITY OF IOWA FOR VALIDATION THROUGH A FEE-FOR-SERVICE SUBCONTRACT. JP2MRI IS CONTINUING TO REFINE OUR VACCINE DEVELOPMENT EFFORTS IN ORDER TO ADDRESS THE NEED FOR A BETTER ETHICALLY DEVELOPED VACCINE. 267357 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 7 1 0 0 0 0 0 0 0 0 0 0 X 6 4 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 0 0 0 X X JAY KAMATH 3196887367 2500 CROSSPARK RD E108 IOWA CITY IA 52241 JAY KAMATH PRESIDENT 5.00 X X 71523 0 2076 DR ALAN MOY VICE PRESIDENT 5.00 X X 40000 0 0 JEANNE MOY DIRECTOR 0.25 X 0 0 0 ISAAC DOUCETTE DIRECTOR 0.25 X 0 0 0 DR JAMES BECKER DIRECTOR 0.25 X 0 0 0 DR MARTIN BEDNAR DIRECTOR 0.25 X 0 0 0 111523 0 2076 0 0 0 0 0 2000 462437 464437 OTHER INCOME 900099 4953 4953 4953 358 358 469748 4953 0 358 111523 40000 71523 38963 38963 60168 19669 40499 11512 6041 5471 3700 3700 9200 9200 5819 2101 3718 75571 1679 73892 34446 34446 1500 1500 2238 2238 2815 2815 2234 2234 RESEARCH & DEVELOPMENT 116880 116880 REIMBURSEMENT 14773 14773 MISCELLANEOUS 10045 10045 SERVICE CHARGE 5662 5662 12711 3263 7906 1542 519760 267357 247143 5260 475055 448000 34352 35676 167861 142381 4000 25480 513407 509156 7000 17553 3818 3125 112381 148282 123199 168960 X 0 0 0 0 390208 340196 390208 340196 513407 509156 -50012 0 X 0 0 0 X 128957 279177 253162 775994 464437 1901727 128957 279177 253162 775994 464437 1901727 338965 1562762 69 27 86 196 358 736 3398 1500 8036 4953 17887 1920350 0.81380 0.86760 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 167861 142381 25480 25480 DR ALAN MOY CURRENT OFFICER OPERATING EXPENSES X 3818 3125 0 1 1 3125 FORM 990, PART VI, SECTION A, LINE 2 ALAN MOY AND JEANNE MOY HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE 990 WAS DISTRIBUTED TO MEMBERS OF THE GOVERNING BODY BEFORE FILING, AND MEMBERS WERE INSTRUCTED TO REVIEW THE FORM AND PROVIDE FEEDBACK, IF ANY. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS ARE REQUIRED TO SUBMIT ANNUAL SURVEYS DISCLOSING ANY CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST.